Antidepressant Escitalopram Most Effective at Preventing Relapse, Study Finds

A comprehensive review published in The Lancet Psychiatry has found that the antidepressant escitalopram was the most effective medication for keeping patients free from depressive symptoms over periods of up to a year. Analyzing data from previous clinical trials involving nearly 10,000 individuals, researchers evaluated more than a dozen common therapies to determine how successfully they prevented relapses.

Following escitalopram, the atypical antidepressant agomelatine and the SNRI duloxetine ranked next in effectiveness. Fluoxetine, widely recognized under the brand name Prozac, placed just behind them. Patients who were prescribed escitalopram were more likely to see lasting symptom improvement and proved less likely to discontinue their prescribed therapy compared to those on fluoxetine.

Escitalopram proved most effective at preventing depression relapse over a one-year period in a major study.

Evaluating Antidepressant Escitalopram in Relapse Prevention

Depression is a widespread condition, affecting approximately one in six people across the United Kingdom. Although appropriate care and support enable significant recovery, the risk of recurrence remains a persistent challenge for many individuals. Current medical guidance routinely advises individuals to remain on antidepressant medication for a minimum of six months following the resolution of symptoms before gradually tapering off under clinical supervision.

While selective serotonin reuptake inhibitors, or SSRIs—such as escitalopram, sertraline, and fluoxetine—remain the standard first-line choice across standard medical guidelines, researchers observed that the differences between the medications were modest. Older options such as tricyclic antidepressants, including amitriptyline, are now prescribed far less often.

Experts stress that the results should not prompt patients who are already doing well to change their prescriptions. Prof Eric Ruhé of Radboud University noted that while the choice must be tailored, the study assists doctors and patients in selecting medications that maintain wellness over time. Dr Sameer Jauhar from Imperial College London emphasized that the research cannot predict individual outcomes, cautioning that patients currently responding well should not switch. Similarly, Prof Allan Young from the Royal College of Psychiatrists pointed out that modest advantages over the long term rarely outweigh personal side-effect profiles and past responses.

Like other drugs in its class, escitalopram carries potential side effects, including weight gain, constipation, and sleep disruption, though these do not affect everyone. According to the NHS, physicians can recommend alternate medication classes, such as SNRIs, if an SSRI proves ineffective or unsuitable. The mental health charity Mind added that individuals frequently try multiple medications before discovering an effective regimen, emphasizing the importance of access to clear information alongside complementary supports such as talking therapies and mindfulness.

Why it matters

This research provides doctors and patients with clearer evidence on how specific antidepressants perform beyond acute recovery. By identifying treatments that maintain symptom relief and lower discontinuation rates over twelve months, clinicians can make better-informed long-term treatment plans while balancing individual side effects and therapy options.